Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Immunosuppressive drugs in clinical transplantation are necessary to inhibit the immune response to donor antigens. Although they are effective in controlling acute rejection, they do not prevent long-term transplant loss from chronic rejection. In addition, immunosuppressive drugs have adverse side effects, including increased rate of infections and malignancies. Adoptive cell therapy with human Tregs represents a promising strategy for the induction of transplantation tolerance. Phase I/II clinical trials in transplanted patients are already underway, involving the infusion of Tregs alongside concurrent immunosuppressive drugs. However, it remains to be determined whether the presence of immunosuppressive drugs negatively impacts Treg function and stability. We tested in vitro and in vivo the effects of tacrolimus, mycophenolate and methylprednisolone (major ISDs used in transplantation) on ex vivo expanded, rapamycin-treated human Tregs. The in vitro results showed that these drugs had no effect on phenotype, function and stability of Tregs, although tacrolimus affected the expression of chemokine receptors and IL-10 production. However, viability and proliferative capacity were reduced in a dose-dependent manner by all the three drugs. The in vivo experiments using a humanized mouse model confirmed the in vitro results. However, treatment of mice with only rapamycin maintained the viability, function and proliferative ability of adoptively transferred Tregs. Taken together, our results suggest that the key functions of ex vivo expanded Tregs are not affected by a concurrent immunosuppressive therapy. However, the choice of the drug combination and their timing and dosing should be considered as an essential component to induce and maintain tolerance by Treg.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coenen, J. J. A., Koenen, H. J. P. M., van Rijssen, E., Hilbrands, L. B., & Joosten, I. (2006) · Blood · doi:10.1182/blood-2005-07-3032 · Cited by 252 · cited 1×
“ferentiation of the highly suppressive CD4CD25CD27 subset upon alloantigen stimulation.(40) In addition, calcineurin inhibitors have been shown to affect Treg stability by directly interfering with NFAT signaling, and, as a consequence, its interaction with FOXP3.”
BackgroundAkimova, T., Kamath, B. M., Goebel, J. W., Meyers, K. E. C., Rand, E. B., Hawkins, A., Levine, M. H., Bucuvalas, J. C., & Hancock, W. W. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04269.x · Cited by 126
In vitro effects of cyclosporine a and tacrolimus on regulatory T-cell proliferation and function
Miroux, C., Morales, O., Ghazal, K., Othman, S. B., de Launoit, Y., Pancré, V., Conti, F., & Delhem, N. (2012) · Transplantation · doi:10.1097/tp.0b013e3182590d8f · Cited by 117 · cited 2×
“Current evidence suggests that calcineurin inhibitors have markedly negative effects on circulating Tregs, mainly by interfering with IL-2 production and therefore affecting Treg function and survival.(11,12) Conversely, corticosteroids have been reported to increase Treg frequency and FOXP3 expression in patients wit…”
BackgroundLuther, C., Adamopoulou, E., Stoeckle, C., Brucklacher-Waldert, V., Rosenkranz, D., Stoltze, L., Lauer, S., Poeschel, S., Melms, A., & Tolosa, E. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802046 · Cited by 93 · cited 1×
“Data showed that this treatment can affect the production of Th1 or Th17 polarizing cytokines produced by innate immune cells, as well as T-cell capability to respond to these cytokines.(47,48) Furthermore, recent in vitro and in vivo studies showed that glucocorticoids can favor the establishment of pro-tolerogenic c…”
Background
Cited by
Past, Present, and Future of Regulatory T Cell Therapy in Transplantation and Autoimmunity
Romano, M., Fanelli, G., Albany, C. J., Giganti, G., & Lombardi, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00043 · Cited by 512
Self-citationRoberts, M. B., & Fishman, J. A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1189 · Cited by 277
Tolerogenic Dendritic Cells in Autoimmunity and Inflammatory Diseases
Morante-Palacios, O., Fondelli, F., Ballestar, E., & Martínez-Cáceres, E. M. (2021) · Trends in Immunology · doi:10.1016/j.it.2020.11.001 · Cited by 263
Treg cell therapy: How cell heterogeneity can make the difference
Giganti, G., Atif, M., Mohseni, Y., Mastronicola, D., Grageda, N., Povoleri, G. A., Miyara, M., & Scottà, C. (2021) · European Journal of Immunology · doi:10.1002/eji.201948131 · Cited by 82
Self-citationThe dark side of Tregs during aging
Palatella, M., Guillaume, S. M., Linterman, M. A., & Huehn, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940705 · Cited by 58
“Indeed, it has been demonstrated that glucocorticoids, which are increased in the elderly population, can enlarge this regulatory population in the periphery (75).”
Background
Metadata
- Authors
- Scotta, C., Fanelli, G., Hoong, S. J., Romano, M., Lamperti, E. N., Sukthankar, M., Guggino, G., Fazekasova, H., Ratnasothy, K., Becker, P. D., Afzali, B., Lechler, R. I., & Lombardi, G.
- Venue
- Haematologica
- Published
- 2015-10-15
- Volume
- 101
- Issue
- 1
- Pages
- 91-100
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- OpenAlex
- W2243664192
- Cited by
- 82
- References
- 4
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells. https://app.cochat.ai/papers/10.3324/haematol.2015.128934
- The paper
- Scotta, C., Fanelli, G., Hoong, S. J., Romano, M., Lamperti, E. N., Sukthankar, M., Guggino, G., Fazekasova, H., Ratnasothy, K., Becker, P. D., Afzali, B., Lechler, R. I., & Lombardi, G. (2016). Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells. Haematologica. https://doi.org/10.3324/haematol.2015.128934
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.